, Volume 219, Issue 4, pp 1179-1181

The lack of effect of ziprasidone on platelet serotonin concentration in schizophrenic patients

Rent the article at a discount

Rent now

* Final gross prices may vary according to local VAT.

Get Access
This is an excerpt from the content

Ziprasidone is an atypical antipsychotic, with higher ratio of 5-HT2A/D2, 5-HT2C/D2 and 5-HT1A/D2 receptor binding than other antipsychotic drugs (Schmidt et al. 2001; Stahl and Shayegan 2007). It also blocks the serotonin transporter (5-HTT) and inhibits synaptic 5-HT reuptake (Tatsumi et al. 1999). Drugs that block the 5-HTT such as selective serotonin reuptake inhibitors (SSRI) have antidepressant properties, and ziprasidone is reported to have antidepressant effects in patients with depression (Moeller et al. 2007; Stahl and Shayegan 2007). At present, however, it is unknown whether ziprasidone affects the 5-HTT in vivo when given to patients in therapeutic doses. Platelet 5-HT concentration is a reliable marker of the 5-HTT blockade induced by SSRI, and reduced platelet 5-HT concentration is used as a marker of the biological activity of various SSRI (Muck-Seler et al. 2002). Therefore, the aim of the study was to investigate the effect of ziprasidone treatment on platelet 5-HT co